PMID- 33322143
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20240330
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 24
DP  - 2020 Dec 13
TI  - Monoclonal Antibodies and Airway Diseases.
LID - 10.3390/ijms21249477 [doi]
LID - 9477
AB  - Monoclonal antibodies, biologics, are a relatively new treatment option for 
      severe chronic airway diseases, asthma, allergic rhinitis, and chronic 
      rhinosinusitis (CRS). In this review, we focus on the physiological and 
      pathomechanisms of monoclonal antibodies, and we present recent study results 
      regarding their use as a therapeutic option against severe airway diseases. 
      Airway mucosa acts as a relative barrier, modulating antigenic stimulation and 
      responding to environmental pathogen exposure with a specific, self-limited 
      response. In severe asthma and/or CRS, genome-environmental interactions lead to 
      dysbiosis, aggravated inflammation, and disease. In healthy conditions, single or 
      combined type 1, 2, and 3 immunological response pathways are invoked, generating 
      cytokine, chemokine, innate cellular and T helper (Th) responses to eliminate 
      viruses, helminths, and extracellular bacteria/fungi, correspondingly. Although 
      the pathomechanisms are not fully known, the majority of severe airway diseases 
      are related to type 2 high inflammation. Type 2 cytokines interleukins (IL) 4, 5, 
      and 13, are orchestrated by innate lymphoid cell (ILC) and Th subsets leading to 
      eosinophilia, immunoglobulin E (IgE) responses, and permanently impaired airway 
      damage. Monoclonal antibodies can bind or block key parts of these inflammatory 
      pathways, resulting in less inflammation and improved disease control.
FAU - Lyly, Annina
AU  - Lyly A
AUID- ORCID: 0000-0001-7221-1227
AD  - Inflammation Centre, Skin and Allergy Hospital, Helsinki University Hospital, 
      University of Helsinki, P.O. Box 160, 00029 HUS Helsinki, Finland.
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University 
      Hospital, University of Helsinki, 00029 HUS Helsinki, Finland.
FAU - Laulajainen-Hongisto, Anu
AU  - Laulajainen-Hongisto A
AUID- ORCID: 0000-0001-5109-6944
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University 
      Hospital, University of Helsinki, 00029 HUS Helsinki, Finland.
FAU - Gevaert, Philippe
AU  - Gevaert P
AD  - Department of Otorhinolaryngology, Upper Airway Research Laboratory, Ghent 
      University Hospital, 9000 Ghent, Belgium.
FAU - Kauppi, Paula
AU  - Kauppi P
AUID- ORCID: 0000-0002-1065-330X
AD  - Heart and Lung Center, Pulmonary Department, University of Helsinki and Helsinki 
      University Hospital, 00029 HUS Helsinki, Finland.
FAU - Toppila-Salmi, Sanna
AU  - Toppila-Salmi S
AUID- ORCID: 0000-0003-0890-6686
AD  - Inflammation Centre, Skin and Allergy Hospital, Helsinki University Hospital, 
      University of Helsinki, P.O. Box 160, 00029 HUS Helsinki, Finland.
AD  - Medicum, Haartman Institute, University of Helsinki, 00029 HUS Helsinki, Finland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201213
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cytokines)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Asthma/drug therapy/*immunology
MH  - Cytokines/metabolism
MH  - Humans
MH  - Immunity, Innate
MH  - Inflammation/*immunology/metabolism
MH  - Respiration Disorders/drug therapy/*immunology
MH  - Rhinitis, Allergic/drug therapy/*immunology
MH  - Sinusitis/drug therapy/*immunology/metabolism
MH  - T-Lymphocytes, Helper-Inducer/immunology
PMC - PMC7763928
OTO - NOTNLM
OT  - airways
OT  - asthma
OT  - biologicals
OT  - chronic rhinosinusitis
OT  - monoclonal antibody
COIS- S.T.-S. reports a grant of GSK and consultancies for AstraZeneca, ERT, Novartis, 
      Sanofi Pharma and Roche. All these are outside the submitted work. P.G. is a 
      speaker and advisory board member for Ablynx, ALK, Argenx, AstraZeneca, 
      Genentech, Inc., Hal Allergy, Novartis, Regeneron, Roche, Sanofi, and 
      Stallergenes. All other authors declare no conflicts of interest.
EDAT- 2020/12/17 06:00
MHDA- 2021/03/20 06:00
PMCR- 2020/12/13
CRDT- 2020/12/16 01:02
PHST- 2020/11/25 00:00 [received]
PHST- 2020/12/09 00:00 [revised]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2020/12/16 01:02 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2020/12/13 00:00 [pmc-release]
AID - ijms21249477 [pii]
AID - ijms-21-09477 [pii]
AID - 10.3390/ijms21249477 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Dec 13;21(24):9477. doi: 10.3390/ijms21249477.